
EU GMP Annex 22: AI Pulse Check panelists say most manufacturers aren’t ready, static AI models likely stay central, and local AI deployment grows.
What’s the best way to reach first-in-man studies when you have little to no information? Bioavailability issues, financial constraints.
What’s the best way to reach first-in-man studies when you have little to no information? Bioavailability issues, financial constraints, and pressure to meet accelerated deadlines can affect development, so having a firm plan in place is key. PharmTech is hosting a free educational





